Moving beyond the mousetrap: current and emerging humanized mouse and rat models for investigating prevention and cure strategies against HIV infection and associated pathologies

Yash Agarwal†, Cole Beatty†, Shivkumar Biradar†, Isabella Castronova†, Sara Ho†, Kevin Melody‡ and Moses Turkle Bility‡†

Abstract

The development of safe and effective combination antiretroviral therapies for human immunodeficiency virus (HIV) infection over the past several decades has significantly reduced HIV-associated morbidity and mortality. Additionally, antiretroviral drugs have provided an effective means of protection against HIV transmission. Despite these advances, significant limitations exist; namely, the inability to eliminate HIV reservoirs, the inability to reverse lymphoid tissues damage, and the lack of an effective vaccine for preventing HIV transmission. Evaluation of the safety and efficacy of therapeutics and vaccines for eliminating HIV reservoirs and preventing HIV transmission requires robust in vivo models. Since HIV is a human-specific pathogen, that targets hematopoietic lineage cells and lymphoid tissues, in vivo animal models for HIV-host interactions require incorporation of human hematopoietic lineage cells and lymphoid tissues. In this review, we will discuss the construction of mouse models with human lymphoid tissues and/or hematopoietic lineage cells, termed, human immune system (HIS)-humanized mice. These HIS-humanized mouse models can support the development of functional human innate and adaptive immune cells, along with primary (thymus) and secondary (spleen) lymphoid tissues. We will discuss applications of HIS-humanized mouse models in evaluating the safety and efficacy of therapeutics against HIV reservoirs and associated immunopathology, and delineate the human immune response elicited by candidate HIV vaccines. In addition to focusing on how these HIS-humanized mouse models have already furthered our understanding of HIV and contributed to HIV therapeutics development, we discuss how emerging HIS-humanized rat models could address the limitations of HIS-mouse models.

Keywords: Humanized mouse and rat models, Modeling HIV infection and reservoir, Modeling human anti-HIV immune response, In vivo models for HIV cure, Animal models for HIV vaccines

Background

Despite combination antiretroviral therapy (cART)-mediated suppression of human immunodeficiency virus (HIV) replication and promotion of immune reconstitution in patients, HIV-associated morbidity persists and is associated with the latent reservoir, unresolved immune abnormalities, and fibrosis in lymphoid organs [1].
Additionally, HIV transmission remains endemic across the globe, and development of a functional cure and/or an effective vaccine will be required to end this epidemic [2]. HIV is a human specific pathogen; thus, animal models for evaluating the safety and efficacy of therapeutics and vaccines directly against HIV requires the incorporation of human lymphoid tissues and/or hematopoietic lineage cells. Such mouse models exist, and are termed, human immune system (HIS)-humanized mice [3, 4]. To construct HIS-humanized mice, immunodeficient mice are myoablated to eradicate residual mouse bone marrow stem cells, and then engrafted with human peripheral blood mononuclear cells (PBMCs) or human hematopoietic stem cells (HSC) with or without transplantation of lymphoid tissues, such as thymus and/or spleen [5]. Over a period of a few weeks to months, transplanted mice develop human immune cells, and reconstitution is confirmed by flow cytometry [5] (Fig. 1). HIS-humanized mice can then be employed in studies investigating HIV prevention or cure strategies [5]. In this review, we will discuss the myriad of approaches for developing HIS-humanized mouse models, and their applications in HIV therapeutics and vaccine development studies, along with their limitations. Finally, we will discuss the potential of an emerging HIS-humanized rat model, which has a longer lifespan and greater physiological similarity to humans compared to mice, designed to enable longitudinal studies in evaluating therapeutics against HIV reservoirs and vaccine-induced immunity [6, 7].

**Humanized mice that incorporate human immune cells**

**Peripheral blood lymphocytes (PBL)-humanized mouse model**

Human CD4+ T cells are the major target for HIV infection; thus, a mouse model with human CD4+ T cells provides a platform for modeling HIV/AIDS. Various immunodeficient mouse models lacking mature T, B, [8] and NK cells, along with defects in macrophage phagocytic function [9] support robust reconstitution of human CD4+ T cells and other lymphocytes (e.g. CD8+ T cells) following transplantation of human PBMCs or CD4+ T cells. Such cells can be transplanted via intravenous (IV) or intraperitoneal (IP) injection into myoablated, immunodeficient juvenile mice (6–8 weeks old) at a dose of 5–10 × 10^6 cell per mouse, to generate peripheral blood lymphocyte (PBL)-humanized mice. Human CD4+ T cells are readily detectable in the blood...
at 4 weeks post-transplantation [9, 10], hence providing a humanized mouse model that can be generated in a relatively short period. The PBL-humanized mouse model supports HIV replication and provides a means of evaluating the efficacy of direct-acting therapeutics (e.g. antivirals drugs, antibodies) geared towards preventing HIV transmission [11] and controlling HIV replication [9]. Additionally, PBL-humanized mouse models constructed using PBMCs from HIV-infected individuals with undetectable viral load can be employed as an in vivo assay (mouse-quantitative viral outgrowth assay) for evaluating the eradication of the HIV reservoir in said individuals [12, 13]. A major limitation of this model is the rapid development of graft-versus-host (GvHD) disease within 6–7 weeks following transplantation of lymphocytes, thus significantly restricting the experimental window [14]. Additionally, the PBL-humanized mouse model does not incorporate human macrophages, which are a major HIV reservoir in various organs, including the brain [9, 15]. However, modification of the PBL-humanized mouse model via transplantation of HIV-infected monocyte-derived macrophages in the brain supports HIV infection and pathogenesis in the brain [15].

**Hematopoietic stem cells (HSC)-humanized mouse model**

In order to generate a de novo human immune system and reconstitute a broader spectrum of human immune cells in HIS-humanized mice, myoablated, immunodeficient mice are transplanted with human CD34+ HSCs via intraperitoneal or intracardiac injection in neonatal mice [10, 16] or IV injection in juvenile/adult mice [16, 17]. These HSCs can be obtained from a myriad of sources, including fetal liver tissue [17, 18] and neonatal cord blood cells [4, 16, 19]. Human immune reconstitution in the HSC-humanized mouse model requires 10–12 weeks to develop [20]. Various hematopoietic lineages, including T cells, monocytes/macrophages, B cells and dendritic cells are developed in the blood and other tissues (e.g., spleen, liver, brain) [20]. Moreover, the HSC-humanized mouse model generates a naïve human immune system, which negates confounding factors associated with prior pathogen exposure [16, 21]. The HSC-humanized mouse model supports HIV infection, CD4+ T cell depletion, chronic immune activation and limited anti-HIV T and B cell immune responses [4]. A major advantage of the HSC-humanized mouse model over the PBL-humanized mouse model is the delayed and reduced incidence of GvHD, which provides the opportunity for long-term modeling of HIV infection and replication [9]. The HSC-humanized mouse model provides a means of evaluating the efficacy and safety of direct-acting therapeutics (e.g. antivirals drugs, antibodies) and immune-modulatory agents (e.g. pDC modulators [22]) geared towards preventing HIV transmission, controlling HIV replication, and ameliorating CD4+ T cell depletion and chronic immune activation [4]. The HSC-humanized mouse model supports HIV transmission via the IV (along with IP) route [18]; however, conflicting reports exist for the mucosal route of transmission [23, 24]. Additionally, the reconstituted human T cells are educated in the mouse thymic epithelium, thus limiting antigen-specific responses [25]. This limitation of T cell education in the murine thymic epithelium has been partially overcome by the construction human leukocyte antigen (HLA) class I transgenic-immunodeficient mice to support robust T cell development of HLA-matched HSC transplants [26]. Moreover, lymph nodes and spleen are poorly reconstituted, including a limited development of human B and myeloid cells in the white and red pulps of the spleen [27]. Several modifications have been made to the HSC model to address these limitations. Li et al. constructed an immunodeficient mouse model that incorporated a lymphoid tissue-stromal cytokine transgene (i.e. thymic-stromal-cell-derived lymphopoietin) and demonstrated improved lymph node development in HSC-humanized mice [27]. Additionally, studies have demonstrated enhanced human B and myeloid cell development in murine secondary lymphoid tissues via transgenic expression of critical cytokines (i.e. IL6; IL3, GM-CSF and SCF) for B and myeloid cell maturation [28–30]. Although incorporation of requisite human transgenes in HIS-humanized mice has been successful in demonstrating improved development of immune cells, often the resultant lineage is skewed, as the transgene expression is not synchronized for physiological expression and supporting stromal cells and other essential cytokines are absent [28–30].

**Humanized mice that incorporate human immune cells and lymphoid tissues**

**Bone marrow–liver–thymus (BLT)-humanized mouse model**

Another strategy for improving human immune cell development in HIS-humanized mouse models is to implant human lymphoid tissues containing the requisite microenvironment for supporting robust immune cell development. To facilitate human T cell education and associated function, human thymic tissues are incorporated in HIS-humanized mice, and termed, Bone marrow–liver–thymus (BLT)-humanized mice [31, 32] (Fig. 2). BLT-humanized mice have served as a key animal model for HIV research for over a decade and are a cost-effective alternative to the surrogate, simian immunodeficiency virus (SIV)-non-human primate (NHP) models. The BLT-humanized mouse model is generated by surgically transplanting myoablated, immunodeficient
mice with fetal human liver and thymus tissues, followed by IV injection of autologous CD34+ HSCs [31, 33, 34]. Transplanted mice require 10–12 weeks for systemic reconstitution of human cells post-transplantation [31, 33, 34]. The most widely utilized strain for constructing BLT mice is the NOD-PrkdcscidIL2rgTm1Wjll (NSG) [21, 32], which is readily available from Jackson Laboratory. BLT-humanized mice can also be constructed using comparable immunodeficient mouse strains, such as, C57BL/6 Rag2−/−γc−/−CD47−/− (TKO) [21, 35]. The key benefit of the BLT-humanized mouse model over PBL- and HSC-humanized mouse models is the presence of human thymic microenvironment, which facilitates T cell education in an autologous human tissue that contains the requisite stromal cells (as well as cytokines and factors, presumably at physiological levels) [21]. BLT-humanized mice have systemic tissue reconstitution with human immune cells, including in mucosal tissues, which enables mucosal transmission [36–43] and recapitulates the main route of HIV transmission in humans [36–44]. Other hallmarks of HIV infection and replication in BLT-humanized mice include robust T cell depletion [36, 42], central nervous system infiltration [45, 46], immune response [35, 47–50], and latency [51–53]. The BLT-humanized mouse model is a robust platform for evaluating HIV prevention and cure strategies, including antiretroviral therapy, pre-exposure prophylaxis (PrEP), latency reversing agents (LRA), vaccination, proviral excision, and T cell engineering (Table 1).

Despite significant advances gained from the BLT-humanized mouse model, the system does have some disadvantages. Construction of BLT-humanized mice requires advanced surgical expertise and extensive experience; therefore, these animals are constructed predominantly by specialized core facilities. Additionally, BLT-humanized mice are prone to GvHD, which limits the experimental window these animals can be utilized to approximately 6 months post-engraftment [54, 55]. However, BLT-humanized mice constructed with a C57BL/6 immunodeficient background are resistant to GvHD [35, 53]. Another disadvantage involves the use of human fetal tissues in constructing the model; these tissues are not readily available. Furthermore, a typical human fetal thymus and autologous fetal liver-derived HSCs can only support the construction of 15–25 BLT-humanized mice. The limited availability of said human fetal tissues creates logistical and operational constraints. Recently, a novel BLT-like humanized mouse model has been developed using non-autologous human cord blood-derived HSCs and human neonatal/pediatric thymus, which enable investigators to construct >1000 BLT-like humanized mice using cryopreserved thymus tissues and readily available cord blood-derived HSCs [96]. Recent studies demonstrate that these BLT-like humanized mice develop human immune cells, support HIV infection and replication, and exhibit anti-HIV immune response (unpublished data from Elie Haddad, Chloé Colas, et al., at the CanCure 5th Annual General Meeting—2019, Poster Session, in Montreal, Canada). Despite systemic immune cell reconstitution and HIV-specific immune responses, both neonatal/pediatric tissue- and fetal tissue-derived BLT-humanized mouse models BLT mice do not develop a complete human immune system. The current widely used immunodeficient mouse models possess an IL-2 receptor γ chain deletion [97–100]. As a result, mouse lymphoid organs do not fully develop in such models, [21] and the loss of lymphoid tissue microenvironment impairs the ability of BLT-humanized mice to develop a robust humoral immune response, as immunoglobulins are skewed towards IgM or weak IgG response [35, 49, 99, 101–103]. Constructing BLT-humanized mice using immunodeficient mouse models with requisite human transgenic factors/cytokines, may optimize human B cell development and overcome the limitations of humoral immune response in the model [28, 104, 105]. An alternative strategy, which is consistent with the BLT-model...
| Strategy                          | Therapeutic agent(s)                                                                 | Reference(s) |
|----------------------------------|--------------------------------------------------------------------------------------|--------------|
| **Antiviral therapy**            | dCA                                                                                  | [45, 56]     |
|                                  | EFdA                                                                                 | [57]         |
|                                  | RAL                                                                                  | [45]         |
|                                  | PD-1 mAb                                                                             | [58]         |
|                                  | PG16 bNAb                                                                            | [59]         |
|                                  | PGT121 bNAb                                                                          | [60]         |
|                                  | 3TC, TDF                                                                             | [61]         |
|                                  | AZT, ddI, IDV                                                                         | [52]         |
|                                  | FTC, RPV, DTG                                                                         | [46, 57]     |
|                                  | FTC, TAF, EVG                                                                         | [62]         |
|                                  | FTC, TDF, DTG                                                                         | [37, 46, 51, 53, 63] |
|                                  | FTC, TDF, RAL                                                                         | [37, 46, 51, 63] |
|                                  | FTC, TDF, RAL, 3B3(Fv)-PE38 immunotoxin                                              | [64]         |
|                                  | FTC, TDF, RAL, IFNα14                                                                  | [61, 65]     |
| **Pre-exposure prophylaxis (PrEP)** | CSA peptide                                                                          | [66]         |
|                                  | Cc-griffithsin                                                                        | [67]         |
|                                  | CD4 AsiCs                                                                            | [68]         |
|                                  | CD4-expressing *Lactobacillus acidophilus*                                            | [69]         |
|                                  | CD4mc P-III-48                                                                        | [70]         |
|                                  | DTG-ultra LA                                                                          | [71]         |
|                                  | EFdA                                                                                 | [72]         |
|                                  | G2-S16 PCD                                                                           | [73]         |
|                                  | IgA                                                                                  | [74]         |
|                                  | MVC                                                                                  | [75]         |
|                                  | RAL-LA                                                                               | [76]         |
|                                  | RPV-LA                                                                               | [39, 77]     |
|                                  | siCCR5 LFA-1-tsNP                                                                     | [78]         |
|                                  | TNV gel                                                                              | [79–81]      |
|                                  | VRC01 bNab                                                                            | [82]         |
|                                  | FTC, TAF                                                                             | [83]         |
|                                  | FTC, TDF                                                                             | [36, 43, 84, 85] |
|                                  | TAF, EVG                                                                             | [86]         |
|                                  | b12, VRC01, VRC07 G54W bNAb                                                          | [87]         |
| **Latency-reversing agents (LRAs)** | AZD5582                                                                              | [88]         |
|                                  | panobinostat                                                                          | [89]         |
|                                  | SUW133 (bryostatin analog)                                                            | [90]         |
| **Vaccines**                    | PLGA-Gag microparticles                                                               | [49, 91]     |
|                                  | Recombinant GP140Δ683                                                                  | [49, 91]     |
| **Proviral excision**            | saCas9/sgRNA                                                                         | [92]         |
| **T cell engineering**           | CCR5 shRNA                                                                           | [93, 94]     |
|                                  | CD4 CAR                                                                              | [95]         |

3TC, lamivudine; AsiCs, aptamer-siRNA chimeras; AZT, zidovudine; bNAb, broadly neutralizing antibody; CCR5, C–C chemokine receptor type 5; CAR, chimeric antigen receptor; CD4, cluster of differentiation 4; CD4mc, CD4 mimetic compound; Cc, *Caulobacter crescentus* recombinant expressing; dCA, didehydro-Cortistatin A; ddI, didanosine; DTG, dolutegravir; DTG-ultra LA, long acting dolutegravir; EFdA, 4′-ethynyl-2-fluoro-2′-deoxyadenosine; EVG, elvitegravir; FTC, emtricitabine; IDV, indinavir; IFNα14, interferon α subtype 14; IgA, immunoglobulin A; LFA-1 I-tsNP, lymphocyte function-associated antigen-1 integrin-targeted and stabilized nanoparticle; mAb, monoclonal antibody; MVC, maraviroc; PCD, polyanionic carbosilane dendrimers; PD-1, programmed cell death protein 1; PLGA, poly(lactic-co-glycolic) acid; RAL, raltegravir; RAL-LA, long-acting raltegravir; RPV, rilpivirine; RPV-LA, long acting rilpivirine; saCas9/sgRNA, Staphylococcus aureus CRISPR-associated protein 9/single-guide RNA; shRNA, short hairpin RNA; siCCR5, small interfering RNA CCR5; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; TNV, tenofovir
strategy, is to incorporate the requisite human secondary lymphoid tissue (i.e. spleen) microenvironment for robust human immune cell (e.g. B cells, macrophages) development and response [5].

**Bone marrow–liver–thymus–spleen (BLTS)-humanized mouse model**

To address the limitations of the BLT-humanized mouse model, namely, poor development of secondary lymphoid tissue and modest macrophage reconstitution, we incorporated human spleen into the BLT-humanized mouse model, and termed these animals, Bone marrow–liver–thymus–spleen (BLTS)-humanized mice [5] (Fig. 2). BLTS-humanized mice exhibit significant improvement over the BLT-humanized mice by addressing several limitations [5]. Successful spleen growth dramatically lowers the incidence of GvHD in BLTS-humanized mice, thus allowing for experimental studies that extend up to 9 months post-transplantation [5]. We speculate that the decreased GvHD in BLTS-humanized mice results from appropriate modulation of T cell activation by the human antigen-presenting cells in the human spleen xenograft. The human spleen in the BLTS-humanized mouse model recapitulates human adult spleen architecture and facilitates better reconstitution of immune cells, including human red pulp macrophages, which are poorly reconstituted in the BLT-humanized mouse model [5]. It is well established that macrophages can serve as a reservoir for HIV [106–108]; thus, the BLTS-humanized mouse model provides a system for investigating human splenic macrophage-HIV interactions [5]. Additionally, the spleen is a major lymphoid tissue reservoir, with B cell follicles in the white-pulp serving as an immune privilege site for anti-HIV T-cells [109]. The human spleen in BLTS-humanized mice provides a model for investigating anti-HIV immune response within the white-pulp and the role of B cell follicle in mediating HIV persistence. The BLTS-humanized mouse model supports cART-mediated HIV load suppression, and replication competent HIV reservoirs can be detected in human spleen tissues [5]. Lymphoid tissue fibrosis is an immuno-pathogenic feature associated with HIV infection and plays a major role in mediating chronic inflammation and abrogating the development of a robust immune response [110]. A major advantage of the BLTS-humanized mouse model is that HIV infection results in lymphoid tissue fibrosis; this disease manifestation is absent in HIV-infected BLT-humanized mice [5]. Although the BLTS-humanized mouse model exhibits more robust immune reconstitution compared to its BLT counterpart, the two models share some limitations. The transplantation of the human tissues under the renal capsule requires an individual with advanced surgical skills. The BLTS-humanized mouse model uses human fetal tissues, which introduces logistical and operational constraints. The use of frozen fetal tissues and HSCs can alleviate some of those constraints (unpublished data). Demonstrating robust anti-HIV immunity in HIS-humanized mouse models has been a long-term goal in the field because said system would allow robust evaluation of HIV vaccine candidates against circulating viral strains. The incorporation of human primary and secondary lymphoid tissues in HIS-humanized mice brings us closer to this goal. At present, we are actively investigating the anti-HIV human immunity in the BLTS-humanized mouse model to determine if this system provides a means for evaluating HIV vaccines.

**Emerging human immune system (HIS)-humanized rat model**

Prior to the development of genetic engineering technologies for creating transgenic and knockout mice, rats were the predominant specie of rodents employed in biomedical research [6]. Advantages of using rats include their longer lifespans (~ 3.5 years) and larger size (~ 350 grams), which facilitates longer experimental window and larger sampling volumes compared to the short lifespan (< 1 year) and small size (< 25 g) of mice [6]. Rats provide a more ideal platform for in vivo imaging of diseases, as the larger size of rats provides better resolution [111]. Additionally, rat models exhibit advanced cognitive skills and critical physiological parameters (e.g. heart rate, drug metabolism) that more closely mimic humans [112–115]. Recent advances in genetic engineering, such as the CRISPR/Cas 9 technology has enabled the development of several immunodeficient rat models for transplanting and regenerating human tissues and cells [7, 116–118]. Similar to currently used immunodeficient mouse models, immunodeficient rat models carry mutations in Rag1/2 and IL2rγ genes, with or without SIRP1α transgene [7, 116–118]. A recent study demonstrated that these immunodeficient rats can be reconstituted with a myriad of human immune cells following transplantation with human-fetal liver-derived HSCs and autologous thymus tissues [7] (Fig. 2). These HIS-humanized rat models could provide a means for robust longitudinal studies on the safety and efficacy of therapeutic agents targeting the HIV reservoir. Additionally, HIS-humanized rats could provide a means for modeling HIV-associated end organ diseases, such as cardiovascular, neurocognitive and lung diseases.

**Conclusions**

Despite successful prevention of HIV transmission with antiviral drugs, it is likely that an effective vaccine provides the only means of ending the HIV epidemic [2].
Over the past decades, several promising vaccine candidates have failed in large-scale safety and efficacy clinical trials [2]. The failure of those clinical trials suggests that improved “gate keeper” animal modeling systems are needed for better prediction of vaccine candidate outcomes in human clinical trials [119]. Currently, the surrogate SIV-NHP model is the sole “gate keeper” animal model for determining potential of vaccine candidates [119]. Candidate HIV vaccines selected using this gate-keeper system have been unsuccessful in human clinical trials [119]; suggesting, major improvements in animal modeling are needed. Although significant advancements are still needed in improving HIS-humanized models, several recent advances, such as improved human-secondary lymphoid tissue development, along with the previously developed, robust primary lymphoid tissue development has made it possible to evaluate human immune responses to vaccines [5, 27]. Ideally, these “improved” HIS-humanized mouse models will complement NHP models in addressing critical gaps, such as vaccine-induced immune responses against circulating HIV strains, vaccine safety in the context of HIV transmission, and human-correlates of immunity. Although cART has significantly reduced the morbidity and mortality associated with chronic HIV infection, the HIV reservoir persists in people living with HIV (PLHIV) and is associated with chronic inflammation, lymphoid tissue damage, and a myriad of end-organ diseases [1]. Therefore, eradicating the HIV reservoir and associated chronic inflammation and end organ diseases remains a major challenge. The mechanisms of HIV persistence in PLHIV, despite robust cART-mediated suppression of the virus, are thought to be multifactorial. These factors include persistence in transcriptionally quiescent resting memory CD4+ T cells in the peripheral blood and lymphoid tissues, infection of long-lived resident tissue macrophages in lymphoid tissues and immune privilege organs (e.g. brain, testes, B cell follicle, etc.), and dysregulation in anti-HIV immunity. By virtue of the multitude of factors that play a role in HIV persistence, in vivo models that recapitulate human host-HIV interactions are necessary for determining the safety and efficacy of therapeutic agents for eradicating HIV reservoirs. Improved HIS-humanized mouse models with systemic reconstitution of human immune cells and robust lymphoid tissue development provide a means of evaluating both direct-acting and immune-modulatory HIV-cure therapeutics. Further advances in improving the human-immune system in HIS-humanized mouse and rat models will provide better in vivo systems for evaluating the safety and efficacy of therapeutics and vaccines for HIV prevention and cure.

Abbreviations
HIV: Human immunodeficiency virus; cART: Combination antiretroviral therapy; HIS: Human immune system; PBMCs: Peripheral blood mononuclear cells; PBL: Peripheral blood lymphocytes; HSC: Human hematopoietic stem cells (HSC); CxH: Graft-versus-host (CxH); IV: Intravenous; IP: Intraperitoneal; NOD: NOD-PrkdcscidIl2rgtm1Wjl; TKO: C57BL/6 Rag2−/−; CxM−/−; CD47−/−; BILT: Bone marrow–Liver-Thymus; BLTS: Bone marrow–Liver-thymus–Spleen.

Acknowledgements
Not applicable. Moses Turkle Bility is the senior author

Authors’ contributions
MTB conceived this review and contributed to the preparation of the manuscript. YA, CB, SB, IC, SH and KM contributed equally to the preparation of the manuscript: All authors read and approved the final manuscript.

Funding
This work was supported by the following NIH grants (R21OD024789, (National Institute of Allergy and Infectious Diseases) R21AI135412).

Availability of data and materials
Not applicable.

Ethics approval
The human fetal liver, spleen and thymus (gestational age of 18–20 weeks) used in the transplantations were obtained from medically or elective indicated termination of pregnancy through Magee-Women’s Hospital of University of Pittsburgh Medical Center via the University of Pittsburgh, Health Sciences Tissue Bank. Written informed consent of the maternal donors was obtained in all cases, under IRB of the University of Pittsburgh guidelines and federal/state regulations. The use of human fetal organs/cells to construct humanized mice was reviewed by the University of Pittsburgh’s IRB office, which has determined that this submission does not constitute human subject research as defined under federal regulations (45 CFR 46.102[d or f]) and 21 CFR 56.102[c], [e], and [f]). The use of human hematopoietic stem cells was reviewed and approved by the Human Stem Cell Research Oversight (hSCRO) at the University of Pittsburgh. The use of biological agents (e.g., HIV), recombinant DNA, and transgenic animals was reviewed and approved by the Institutional Biosafety Committee (IBC) at the University of Pittsburgh. All animal studies were approved by the IACUC at the University of Pittsburgh and were conducted following NIH guidelines for housing and care of laboratory animals.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. 2 Galveston National Laboratory and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.

Received: 4 March 2020 Accepted: 31 March 2020
Published online: 10 April 2020

References
1. Ndung’u T, McCune JM, Deeks SG. Why and where an HIV cure is needed and how it might be achieved. Nature. 2019;576(7787):397–405.
2. Bekker LG, Tatoud R, Dabis F, Feinberg M, Kaleebu P, Marovich M, Ndung’u T, Russell N, Johnson J, Luba M, et al. The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet. 2020;395(10221):384–8.
3. Akkina R, Barber DL, Bility MT, Bissig KD, Burwitz BJ, Eichelberg K, Endsley JJ, Garcia JV, Hafner R, Karakousis PC, et al. Small animal models...
for human immunodeficiency virus (HIV), hepatitis B, and tuberculosis: proceedings of an NIAID workshop. Curr HIV Res. 2019;18:19–28.

4. Allen TM, Brehm MA, Bridges S, Ferguson S, Kumar P, Mirochnitchenko Q, Palucka K, Pelanda R, Sanders-Beer B, Shultz LD, et al. Humanized immune system mouse models: progress, challenges and opportunities. Nat Immunol. 2019;20(7):770–4.

5. Samal J, Kelly S, Na-Shatal A, Elhakemi A, Das A, Ding M, Sanyal A, Gupta P, Melody K, Roland B, et al. Human immunodeficiency virus infection induces lymphoid fibrosis in the BM-liver-thymus-spleen humanized mouse model. JCI Insight. 2018;3(18):e120430. https://doi.org/10.1172/jcii.120430.

6. Iannaccone PM, Jacob HJ. Rats! Disease models & mechanisms.

7. Yang X, Zhou J, He J, Liu J, Wang H, Liu Y, Jiang T, Zhang Q, Fu X, Xu Y. An

8. Torbett BE, Picchio G, Mosier DE. hu-PBL-SCID mice: a model for

11. Safrit JT, Fung MSC, Andrews CA, Braun DG, Sun WNC, Chang TW, Koup AR, O, Palucka K, Pelanda R, Sanders-Beer B, Shultz LD, et al. Humanized mouse models to study human immunity: analysis of the functions of human B and T cells in humanized NOD/shi-scid/gamma(null) (NOG) mice (hu-HSC NOG mice). Int Immunol. 2009;21(7):843–58.

12. Metcalf Pate KA, Blankson JN. The mouse viral outgrowth assay: avatars of human immune function, AIDS, and lymphomagenesis. Immunol Rev. 1991;124:139–64.

13. Brehm MA, Cuthbert A, Yang C, Miller DM, DiIorio P, Laning J, Burzenski L, Gott B, Foreman O, Kavirayani A, et al. Parameters for establishing the Engraftment of Hematopoietic Stem Cells. Methods Mol Biol. 2014;1185:267–78.

14. Ali N, Flutter B, Sanchez Rodriguez R, Sharif-Paghaleh E, Barber LD, Lomvardi G, Nestle FO. Xenogeneic graft-versus-host-disease in NOD-scid/gammac-/- (RAG-hu) mice. JCI Insight. 2018;3(18):e120430. https://doi.org/10.1172/jcii.120430.

15. Poluektova LY, Munn DH, Persidsky Y, Gendelman HE. Generation of human immune system-modified rat model for human stem cell transplantation research. Stem Cell Reports. 2018;11(2):514–21.

16. Metcalf Pate KA, Blankson JN. The mouse viral outgrowth assay: avatars of the detection of HIV-1 reservoirs. Retrovirology. 2017;14(1):52.

17. Safrir JT, Fung MSC, Andrews CA, Braun DG, Sun WNC, Chang TW, Koup RA. Hu-PBL-SCid mice can be protected from HIV-1 infection by passive transfer of monoclonal-antibody to the principal neutralizing determinant of envelope Gpl20. Aids. 1993;7(1):15–21.

18. Metcalf Pate KA, Blankson JN. The mouse viral outgrowth assay: avatars for immune system investigation: progress, promise and challenges. Nat Rev Immunol. 2015;15:701–15.

19. Cheng L, Ma J, Li G, Su L. Humanized Mice Engrafted With Human Immune System Cells. Methods Mol Biol. 2014;1185:267–78.

20. Hasgur S, Aryee KE, Shultz LD, Brehm MA. Immunodeficient mouse model for human hematopoietic stem cell transplantation. Methods Mol Biol. 2014;1185:267–78.

21. Denton PW, Estes JD, Sun Z, Dammer P, Osterholm MO, Wei BDL, Wege AK, Rice CM, Ploss A. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol. 2014;32(4):364–72.

22. Billerbeck E, Barry WT, Mu K, Dorner M, Rice CM, Ploss A. Development and function of human CD4+ FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rgamma(null) humanized mice. Blood. 2011;117(11):3076–86.

23. Lan R, Nomura M, Shimizu A, Wang SM, Yang YG. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34(+)- cell transplantation. Blood. 2006;108(2):487–92.

24. Denton PW, Estes JD, Sun ZF, Othieno FA, Wei BDL, Wege AK, Powell DA, Payne D, Haase AT, Garcia JV. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 2008;5(1):79–89.

25. Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Honeycutt JB, Saito Y, Marches F, Haleene S, Paluca AK, et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol. 2014;32(4):364–72.

26. Billerbeck E, Barry WT, Mu K, Dorner M, Rice CM, Ploss A. Development and function of human CD4+ FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rgamma(null) humanized mice. Blood. 2011;117(11):3076–86.

27. Denton PW, Estes JD, Sun Z, Othieno FA, Wei BDL, Wege AK, Powell DA, Payne D, Haase AT, Garcia JV. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 2008;5(1):79–89.

28. Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Honeycutt JB, Saito Y, Marches F, Haleene S, Paluca AK, et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol. 2014;32(4):364–72.

29. Billerbeck E, Barry WT, Mu K, Dorner M, Rice CM, Ploss A. Development and function of human CD4+ FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rgamma(null) humanized mice. Blood. 2011;117(11):3076–86.

30. Lan R, Nomura M, Shimizu A, Wang SM, Yang YG. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34(+)- cell transplantation. Blood. 2006;108(2):487–92.
40. Olesen R, Wahl A, Denton PW, Garcia JV. Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection. J Reprod Immunol. 2011;88(2):195–203.

41. Stoddart CA, Maidji E, Galkina SA, Kosikova G, Rivera JM, Moreno ME, Sloan B, Joshi P, Long BR. Superior human leukocyte reconstitution and susceptibility to vaginal HIV transmission in humanized NOD-scid IL-2Rgamma(-/-) (NSG) BLT mice. Virology. 2011;417(1):154–60.

42. Sun Z, Denton PW, Estes JD, Othieno FA, Wei BL, Wege AK, Melkus MW, Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol. 2011;88(2):195–203.

43. Asahchop EL, Meziane O, Mamik MK, Chan WF, Branton WG, Resch L, Gill KA, Honeycutt JB, Liao B, Nixon CC, Cleary RA, Thayer WO, Birath SL, Padgett-Thomas A, Zupancic M, Haase AT, et al. Intrarectal transmission in BLT-humanized mouse model. PLoS Pathog. 2012;8(6):e1002732.

44. Dudek TE, No DC, Seung E, Vrbanac VD, Fadda L, Bhoumik P, Boutwell MA, Kovarova M, Nicholson AE, Kashuba AD, Smith AB 3rd, Swanson MD, Sheridan P, Zakharova O, Prince F, et al. T cells establish latency in humanized BLT mice. J Virol. 2009;83(14):7305–21.

45. Marsden MD, Kovochich M, Suree N, Shimizu S, Mehta R, Cortado R, Honeycutt JB, Liao B, Nixon CC, Cleary RA, Thayer WO, Birath SL, Padgett-Thomas A, Zupancic M, Haase AT, et al. Intrarectal transmission in BLT-humanized mouse model. PLoS Pathog. 2012;8(6):e1002732.

46. Kessing CF, Nixon CC, Li C, Powers KA, Gladden AD, Battis L, et al. Rapid evolution of HIV-1 to viral persistence in brain. Retrovirology. 2017;14(1):47.

47. Liu Q, Tso FY, Kang G, Lu W, Li Y, Fan W, Yuan Z, Destache CJ, Wood C. Early initiation of antiretroviral therapy can functionally control productive HIV-1 infection in humanized-BLT mice. J Acquir Immune Defic Syndr. 2015;69(5):519–27.

48. Mandal S, Kang G, Prathipati PK, Fan W, Li Q, Destache CJ. Long-acting parental combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: a humanized mouse model study. Antiviral Res. 2018;156:85–91.

49. Salgado M, Swanson MD, Pohmeyer CW, Buckheit RW, Wu J, Archin NM, Williams TM, Margolis DM, Siliciano RF, Garcia JV, et al. HLA-B*57 Blocker Siprosavina decreases viral loads. PLoS ONE. 2013;8(1):e77780.

50. Badamchizadeh A, Tartaglia LJ, Abbink P, Bracka CU, Liu P-T, Boyd M, Kirevola M, Mercado NB, Nanayakkara OS, Vrabac BD, et al. Therapeutic efficacy of vectored PG121 gene delivery in HIV-1-infected humanized mice. J Virol. 2018;92:01925.

51. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol. 2008;8(6):447–57.

52. Asahchop EL, Meziane O, Mamik MK, Chan WF, Branton WG, Resch L, Gill KA, Honeycutt JB, Liao B, Nixon CC, Cleary RA, Thayer WO, Birath SL, Padgett-Thomas A, Zupancic M, Haase AT, et al. Intrarectal transmission in BLT-humanized mouse model. PLoS Pathog. 2012;8(6):e1002732.
Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice. PLoS ONE. 2013;8(3):e60024.

Denton PW, Othieno F, Martinez-Torres F, Zou W, Krisho JF, Fleming E, Zein S, Powell DA, Wang A, Kvak YT, et al. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbi-cide candidates. J Virol. 2011;85(15):7932–9.

Destache CJ, Mandal S, Yuan Z, Kang G, Date AA, Lu W, Shibata A, Pham R, Bruck P, Rezich M, et al. Topical tenofovir disoproxil fumarate nanopo- particles prevent HIV-1 vaginal transmission in a humanized mouse model. Antimicrob Agents Chemother. 2016;60(6):3633–9.

Sun M, Li Y, Yuan Z, Lu W, Kang G, Fan W, Li Q. VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice. Adv Virol. 2016;161(9):2449–55.

Mandal S, Kang G, Prathipati PK, Zhou Y, Fan W, Li Q, Destache CJ. Nanoencapsulation introduces long-action phenenomenon to tenofovir alafenamide and etravicitra drug combination: a comparative pre- exposure prophylaxis efficacy study against HIV-1 vaginal transmission. J Control Release. 2019;294:216–25.

Gallay PA, Chatterji U, Kirchhoff A, Gandarilla A, Gunawardana M, Pyles D, Denton PW, Krisko JF, Powell DA, Mathias M, Kwak YT, Martinez-Torres F, Alafenamide and emtricitabine drug combination: a comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission. J Control Release. 2019;294:216–25.

Seung E, Mellors EF, Vrbanac VD, Krupp K, Bisesi A, et al. Immunization with a synthetic bryostatin analog effects both latent cell “kick” and “kill” in strategy for virus eradication. PLoS Pathog. 2017;13(9):e1006575.

Bader M. Rat models of cardiovascular diseases. Methods Mol Biol. 2011;2011:497841.

Brehm MA, Wiles MV, Greiner DL, Shultz LD. Generation of improved humanized mouse models for human infectious diseases. J Immunol Methods. 2014;410:3–17.

Vuyyuru R, Patton J, Manser T. Human immune system mice: current potential and limitations for translational research on human antibody responses. 2011;51(2–3):257–66.
116. He D, Zhang J, Wu W, Yi N, He W, Lu P, Li B, Yang N, Wang D, Xue Z, et al. A novel immunodeficient rat model supports human lung cancer xenografts. FASEB J. 2019;33(1):140–50.

117. Beldick SR, Hong J, Altamentova S, Khazaei M, Hundal A, Zavvarian MM, Rumajogee P, Chio J, Fehlings MG. Severe-combined immunodeficient rats can be used to generate a model of perinatal hypoxic-ischemic brain injury to facilitate studies of engrafted human neural stem cells. PLoS ONE. 2018;13(11):e0208105.

118. Noto FK, Adjan-Steffey V, Tong M, Ravichandran K, Zhang W, Arey A, McClain CB, Ostertag E, Mazhar S, Sangodkar J, et al. Sprague Dawley Rag2-Null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts. Mol Cancer Ther. 2018;17(11):2481–9.

119. Shedlock DJ, Silvestri G, Weiner DB. Monkeying around with HIV vaccines: using rhesus macaques to define gatekeepers for clinical trials. Nat Rev Immunol. 2009;9(10):717–28.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.